[
  {
    "ts": null,
    "headline": "JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra",
    "summary": "Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.",
    "url": "https://finnhub.io/api/news?id=46ee6b6845a8e85450cb3219d3a28ad1500ca2381313b6df1dc338009ba8806b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753199460,
      "headline": "JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra",
      "id": 136033330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.",
      "url": "https://finnhub.io/api/news?id=46ee6b6845a8e85450cb3219d3a28ad1500ca2381313b6df1dc338009ba8806b"
    }
  },
  {
    "ts": null,
    "headline": "AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures",
    "summary": "AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.",
    "url": "https://finnhub.io/api/news?id=2e741b154497c11aacd7734185112b38fb2b6547954a7fd022900bb864a4e989",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753198980,
      "headline": "AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures",
      "id": 136033300,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.",
      "url": "https://finnhub.io/api/news?id=2e741b154497c11aacd7734185112b38fb2b6547954a7fd022900bb864a4e989"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Stock Could Be Waking Up",
    "summary": "Johnson & Johnson's stock offers value with promising MedTech growth, raised guidance, strong dividends, and bullish technical momentum. Learn more on JNJ stock here.",
    "url": "https://finnhub.io/api/news?id=f2ad56709b94b81c370098ebfe197a9a49480cada5a5cf287ca5f90d7d3b2d97",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753197118,
      "headline": "Johnson & Johnson Stock Could Be Waking Up",
      "id": 136034822,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1916635270/image_1916635270.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson's stock offers value with promising MedTech growth, raised guidance, strong dividends, and bullish technical momentum. Learn more on JNJ stock here.",
      "url": "https://finnhub.io/api/news?id=f2ad56709b94b81c370098ebfe197a9a49480cada5a5cf287ca5f90d7d3b2d97"
    }
  },
  {
    "ts": null,
    "headline": "How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?",
    "summary": "ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.",
    "url": "https://finnhub.io/api/news?id=575871e6183099e7c5c71408470fcd8398c2d2ef95611b986cab10f4aa861e38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753191060,
      "headline": "How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?",
      "id": 136033332,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.",
      "url": "https://finnhub.io/api/news?id=575871e6183099e7c5c71408470fcd8398c2d2ef95611b986cab10f4aa861e38"
    }
  },
  {
    "ts": null,
    "headline": "Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?",
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=891f53950af149af5c1056a7468f4c94ee8ba62cded00f87a2503783c92b9878",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753189204,
      "headline": "Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?",
      "id": 136033333,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=891f53950af149af5c1056a7468f4c94ee8ba62cded00f87a2503783c92b9878"
    }
  },
  {
    "ts": null,
    "headline": "Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity",
    "summary": "According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion by 2030, rising at a CAGR of 36.79%. The rising prevalence of eye diseases, advancements in imaging technology, and expansion of teleophthalmology services are factors contributing to market growth. The report said: \"In addition, growing preference for personalized treatment plans and increasing government initiatives fuel market gro",
    "url": "https://finnhub.io/api/news?id=ce2906d2b64f46f4a715f111d8a13162f203186056c617d8e91f3625bcdd1d5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753188300,
      "headline": "Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity",
      "id": 136031281,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion by 2030, rising at a CAGR of 36.79%. The rising prevalence of eye diseases, advancements in imaging technology, and expansion of teleophthalmology services are factors contributing to market growth. The report said: \"In addition, growing preference for personalized treatment plans and increasing government initiatives fuel market gro",
      "url": "https://finnhub.io/api/news?id=ce2906d2b64f46f4a715f111d8a13162f203186056c617d8e91f3625bcdd1d5b"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion",
    "summary": "The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.",
    "url": "https://finnhub.io/api/news?id=5602222cffa11cfdfcef20a299076f62b6c52be7e0a14b6e7cdd9e34fb1ba628",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753185540,
      "headline": "Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion",
      "id": 136031282,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.",
      "url": "https://finnhub.io/api/news?id=5602222cffa11cfdfcef20a299076f62b6c52be7e0a14b6e7cdd9e34fb1ba628"
    }
  },
  {
    "ts": null,
    "headline": "Replimune drug rejected by FDA; Omega raises $647M biotech fund",
    "summary": "Analysts questioned whether the complete response letter Replimune received was evidence of changing approval standards at the FDA.",
    "url": "https://finnhub.io/api/news?id=2ebe8685350aa1e340569835f452838c8c79813fbf619b2284896b7c6d8e57f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753184100,
      "headline": "Replimune drug rejected by FDA; Omega raises $647M biotech fund",
      "id": 136033334,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Analysts questioned whether the complete response letter Replimune received was evidence of changing approval standards at the FDA.",
      "url": "https://finnhub.io/api/news?id=2ebe8685350aa1e340569835f452838c8c79813fbf619b2284896b7c6d8e57f8"
    }
  },
  {
    "ts": null,
    "headline": "Buy Now or Regret Later: This Small-Cap Stock Has Big Disruption Potential",
    "summary": "This small-cap biotech might be volatile in the short term but could offer genuine long-term upside with its disruptive innovation.",
    "url": "https://finnhub.io/api/news?id=60b16b4fe518bb985258040e891c9c8a62096302c77cde810c8ae36dcaf5bc4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753183802,
      "headline": "Buy Now or Regret Later: This Small-Cap Stock Has Big Disruption Potential",
      "id": 136031283,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "This small-cap biotech might be volatile in the short term but could offer genuine long-term upside with its disruptive innovation.",
      "url": "https://finnhub.io/api/news?id=60b16b4fe518bb985258040e891c9c8a62096302c77cde810c8ae36dcaf5bc4e"
    }
  },
  {
    "ts": null,
    "headline": "J&J seeks FDA approval for icotrokinra to treat psoriasis",
    "summary": "Icotrokinra is currently being developed through a licensing and collaboration agreement between Protagonist and J&J.",
    "url": "https://finnhub.io/api/news?id=07427dc2af87564fb19f65927ad8e1267bfc0a9b4ebb67c0464fd59856a16c9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753183335,
      "headline": "J&J seeks FDA approval for icotrokinra to treat psoriasis",
      "id": 136031284,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Icotrokinra is currently being developed through a licensing and collaboration agreement between Protagonist and J&J.",
      "url": "https://finnhub.io/api/news?id=07427dc2af87564fb19f65927ad8e1267bfc0a9b4ebb67c0464fd59856a16c9a"
    }
  },
  {
    "ts": null,
    "headline": "Should You Invest in the VanEck Pharmaceutical ETF (PPH)?",
    "summary": "Sector ETF report for PPH",
    "url": "https://finnhub.io/api/news?id=22ccc0f2ddbb960f6d5a9f674d0a62aa236ba29ab95245c3d6ce8041a2adab58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753179606,
      "headline": "Should You Invest in the VanEck Pharmaceutical ETF (PPH)?",
      "id": 136031225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Sector ETF report for PPH",
      "url": "https://finnhub.io/api/news?id=22ccc0f2ddbb960f6d5a9f674d0a62aa236ba29ab95245c3d6ce8041a2adab58"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Kings: July 2025",
    "summary": "Discover why 14 Dividend Kings outperform the S&P 500 in 2025.",
    "url": "https://finnhub.io/api/news?id=0abfb9a06bfcdd22331e819cff2f63c95a0a2e603f074263e23c8ab514d9f843",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753176661,
      "headline": "Best Dividend Kings: July 2025",
      "id": 136031024,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158691690/image_2158691690.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover why 14 Dividend Kings outperform the S&P 500 in 2025.",
      "url": "https://finnhub.io/api/news?id=0abfb9a06bfcdd22331e819cff2f63c95a0a2e603f074263e23c8ab514d9f843"
    }
  },
  {
    "ts": null,
    "headline": "Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR | Roche, Amgen, and Johnson & Johnson at the Forefront: AnalystView Market Insights",
    "summary": "Bispecific T‑cell engagers now dominate oncology pipelines, with global trial activity up 256% since 2019. FDA has approved more than 15 such drugs, and U.S. spending is projected to hit $12.2billion by 2025, rising to over $50 billion by 2032.San Francisco, USA, July 22, 2025 (GLOBE NEWSWIRE) -- The global bispecific antibodies market is witnessing a transformative surge, projected to grow at an impressive compound annual growth rate (CAGR) of 40.10%, reaching a valuation of approximately USD 1",
    "url": "https://finnhub.io/api/news?id=72e8b4261ba13679e1808ad8c6859abc97a6a92ae2a03a1fa614e23f0eb34337",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753168800,
      "headline": "Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR | Roche, Amgen, and Johnson & Johnson at the Forefront: AnalystView Market Insights",
      "id": 136031286,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Bispecific T‑cell engagers now dominate oncology pipelines, with global trial activity up 256% since 2019. FDA has approved more than 15 such drugs, and U.S. spending is projected to hit $12.2billion by 2025, rising to over $50 billion by 2032.San Francisco, USA, July 22, 2025 (GLOBE NEWSWIRE) -- The global bispecific antibodies market is witnessing a transformative surge, projected to grow at an impressive compound annual growth rate (CAGR) of 40.10%, reaching a valuation of approximately USD 1",
      "url": "https://finnhub.io/api/news?id=72e8b4261ba13679e1808ad8c6859abc97a6a92ae2a03a1fa614e23f0eb34337"
    }
  },
  {
    "ts": null,
    "headline": "Kenvue: Tylenol Can't Ease The Pain, Pricey Stock, Dividend In Vain",
    "summary": "Kenvue faces challenges with declining sales, cash flow risks, and high leverage. Read here for more analysis on KVUE stock.",
    "url": "https://finnhub.io/api/news?id=d419a2267ebf2af7ca15de868c057cffaec1fecc3ed6ab4cc1cc040448a948a2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753162205,
      "headline": "Kenvue: Tylenol Can't Ease The Pain, Pricey Stock, Dividend In Vain",
      "id": 136030264,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/494180077/image_494180077.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Kenvue faces challenges with declining sales, cash flow risks, and high leverage. Read here for more analysis on KVUE stock.",
      "url": "https://finnhub.io/api/news?id=d419a2267ebf2af7ca15de868c057cffaec1fecc3ed6ab4cc1cc040448a948a2"
    }
  },
  {
    "ts": null,
    "headline": "NYC Council's Firewall Starts in District 5--with a Bombshell Named Alina",
    "summary": "Alina Bonsell, running for New York City Council in District 5, has been called a bombshell. And sure, people assume that means something about her looks—but in this case, it's about impact. Her last name may get mispronounced (or mistaken for a Freudian slip), but her mission is crystal clear: she's here to shatter the old political mold.",
    "url": "https://finnhub.io/api/news?id=883b5d786db84b06c260a2a7c7c2cc83ba5304c313dbeeb47022b20dae95bd95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753159080,
      "headline": "NYC Council's Firewall Starts in District 5--with a Bombshell Named Alina",
      "id": 136031287,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Alina Bonsell, running for New York City Council in District 5, has been called a bombshell. And sure, people assume that means something about her looks—but in this case, it's about impact. Her last name may get mispronounced (or mistaken for a Freudian slip), but her mission is crystal clear: she's here to shatter the old political mold.",
      "url": "https://finnhub.io/api/news?id=883b5d786db84b06c260a2a7c7c2cc83ba5304c313dbeeb47022b20dae95bd95"
    }
  },
  {
    "ts": null,
    "headline": "Is Kenvue (KVUE) a Halal Dividend Stock Worth Adding to Your Portfolio?",
    "summary": "Kenvue Inc. (NYSE:KVUE) is included among the 11 Best Halal Dividend Stocks to Buy Now. In August 2023, Johnson & Johnson separated its consumer health and hygiene products into a new publicly listed company called Kenvue Inc. (NYSE:KVUE). The new entity manages a portfolio of well-recognized brands across various product categories. Thanks to its international presence, […]",
    "url": "https://finnhub.io/api/news?id=5aa6365b01fb705bbdf995c13c2659627d05b9a455656818ed8cf74b554f1f18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753155556,
      "headline": "Is Kenvue (KVUE) a Halal Dividend Stock Worth Adding to Your Portfolio?",
      "id": 136031288,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Kenvue Inc. (NYSE:KVUE) is included among the 11 Best Halal Dividend Stocks to Buy Now. In August 2023, Johnson & Johnson separated its consumer health and hygiene products into a new publicly listed company called Kenvue Inc. (NYSE:KVUE). The new entity manages a portfolio of well-recognized brands across various product categories. Thanks to its international presence, […]",
      "url": "https://finnhub.io/api/news?id=5aa6365b01fb705bbdf995c13c2659627d05b9a455656818ed8cf74b554f1f18"
    }
  }
]